Spero Therapeutics Inc

2HA

Company Profile

  • Business description

    Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

  • Contact

    675 Massachusetts Avenue
    14th Floor
    CambridgeMA02139
    USA

    T: +1 857 242-1600

    E: [email protected]

    https://www.sperotherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    32

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.7056.700.65%
CAC 407,738.4275.830.99%
DAX 4023,790.11116.820.49%
Dow JONES (US)44,496.341.400.00%
FTSE 1008,774.6910.64-0.12%
HKSE24,221.41149.130.62%
NASDAQ20,359.81156.920.78%
Nikkei 22539,762.48223.85-0.56%
NZX 50 Index12,784.2949.760.39%
S&P 5006,216.0918.080.29%
S&P/ASX 2008,597.7056.600.66%
SSE Composite Index3,454.792.95-0.09%

Market Movers